Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab

Nat Clin Pract Oncol. 2006 Mar;3(3):165-8; quiz 169. doi: 10.1038/ncponc0430.

Abstract

Background: A 73-year-old woman presented with acute lower back pain, fever, chills and arthralgias. She had previously had a positive protein derivative test with a negative chest X-ray; her medical history was also remarkable for a mitral valve prolapse. Initial symptoms resolved spontaneously without therapy, but fever recurred with associated arthralgias, myalgias, diffuse and worsening lymphadenopathy, splenomegaly, and bilateral pulmonary infiltrates.

Investigations: Physical examination, blood and urine cultures, MRI of the spine, echocardiogram, extensive serologies, serum and urine protein electrophoresis, immunofixation electrophoresis, bone-marrow aspiration and biopsy with flow cytometry, cytogenetics, and gene rearrangement studies, CT scan of the chest, abdomen and pelvis, whole-body PET, and lymph-node biopsy for histological examination, immunohistochemistry, and gene rearrangement studies.

Diagnosis: Angioimmunoblastic T-cell lymphoma.

Management: Steroids (prednisone, methylprednisolone), levofloxacin, isoniazid with pyridoxine, ciclosporin A, methotrexate, alemtuzumab, broad-spectrum antibiotics, Pneumocystis carinii prophylaxis, vancomycin, and clindamycin.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Immunoblastic Lymphadenopathy / diagnosis
  • Immunoblastic Lymphadenopathy / drug therapy*
  • Immunoblastic Lymphadenopathy / etiology
  • Immunoblastic Lymphadenopathy / physiopathology
  • Lymphoma, T-Cell / complications
  • Lymphoma, T-Cell / diagnosis
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / physiopathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Alemtuzumab